Traders should monitor Vafseo's commercial momentum in 2026, particularly patient access expansion and adherence improvements from observed dosing protocols. The anticipated decline in Auryxia revenues due to generic competition could pressure margins, but strong Vafseo growth and robust cash reserves provide runway for pipeline development.
Price Chart
Executive Summary
Akebia Therapeutics reported strong financial results for Q4 and full-year 2025, with total revenues of $57.6 million (Q4) and $236.2 million (full-year), representing significant year-over-year growth. The increase was driven by Vafseo sales following its 2025 U.S. launch and higher Auryxia volumes. The company reported a reduced net loss and expects Vafseo revenue growth in 2026 due to expanded access and improved adherence, though Auryxia revenues are expected to decline due to generic competition.
Key Financial Metrics
Key Facts
- Q4 2025 total revenues: $57.6 million (up from $46.5 million in Q4 2024)
- Full-year 2025 total revenues: $236.2 million (up from $160.2 million in 2024)
- Vafseo net product revenues: $6.2 million in Q4 2025 and $45.8 million for full-year 2025
- Auryxia net product revenues: $48.1 million in Q4 2025 (up from $44.4 million in Q4 2024)
- Net loss reduced to $12.2 million in Q4 2025 from $22.8 million in Q4 2024
- Cash and cash equivalents: $184.8 million as of December 31, 2025 (up from $51.9 million in 2024)
- Company expects significant Vafseo revenue growth in 2026 but anticipates Auryxia revenue decline due to generic competition
Financial Impact
Total revenues increased 24% YoY in Q4 and 48% YoY for full-year 2025, with net loss reduced by 46% YoY in Q4. Cash position increased by $132.9 million year-over-year.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Vafseo | $45.8M | — |
| Auryxia | $181.5M | +19.3% |
Risk Factors
- Auryxia revenues expected to decrease in 2026 due to expanding generic competition
- Vafseo carries a boxed warning for increased risk of death, MI, stroke, and thrombosis
- Forward-looking statements about Vafseo revenue growth are subject to commercial execution risks
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001517022-26-000019 |
| Document: akba-20260226.htm | 0001517022-26-000019 |
| Document: 0001517022-26-000019-index-headers.html | 0001517022-26-000019 |
| Document: 0001517022-26-000019-index.html | 0001517022-26-000019 |
| Document: 0001517022-26-000019.txt | 0001517022-26-000019 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 30, 2026 13w ago | 8-K | $1.14 $0.9326 | ▼ −18.19% | ▼ −21.76% | $0.8650 (−24.12%) |
Apr 30, 2026 22w ago | Press Release | $1.40 $1.27 | ▲ +9.29% | ▲ +12.36% | $0.8650 (+38.21%) |
Feb 26, 2026 31w ago | 8-K | $1.32 $1.02 | ▼ −22.73% | ▼ −30.48% | $0.8650 (−34.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access